Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
21,041
Total Claims
$2.1M
Drug Cost
382
Beneficiaries
$5,442
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-89%
Opioid rate vs peers
0.3% vs 2.2% avg
+286%
Cost per patient vs peers
$5,442 vs $1,411 avg
+26%
Brand preference vs peers
13.3% vs 10.6% avg
Opioid Prescribing
0.3%
Opioid Rate
53
Opioid Claims
$910
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,796 claims · $1.6M
Generic: 18,156 claims · $440K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 142 | $166K |
| Apixaban | 424 | $159K |
| Dulaglutide | 111 | $136K |
| Dapagliflozin Propanediol | 154 | $115K |
| Sitagliptin Phosphate | 156 | $91K |
| Tirzepatide | 26 | $64K |
| Glatiramer Acetate | 12 | $57K |
| Linagliptin | 123 | $49K |
| Semaglutide | 31 | $47K |
| Semaglutide | 15 | $45K |
| Insulin Glargine,hum.Rec.Anlog | 77 | $42K |
| Abacavir/Dolutegravir/Lamivudi | 11 | $41K |
| Insulin Lispro | 47 | $41K |
| Fluticasone/Umeclidin/Vilanter | 29 | $37K |
| Dolutegravir Sodium | 56 | $35K |
Prescribing Profile
Patient Profile
73
Avg Age
60%
Female
1.99
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data